Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Sylentis’ dry eye drug fails to meet primary goals of HELIX trial

Sylentis studied tivanisiran in comparison with artificial tears for the treatment of dry eye disease. Credit: Gordon Wrigley.

  • Sylentis

Go Top